Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) Outcome of discontinuation of imatinib therapy after achieving a molecular remission

Ali, Rıdvan; Özkalemkaş, Fahir; Özçelik, Tülay; Özkocaman, Vildan; Ozan, Ülkü; Kimya, Yalçın; Köksal, Nilgün; Gülten, Tuna; Yakut, Tahsin; Tunalı, Ahmet

doi:10.1016/j.leukres.2005.01.009

« Previous Next »Leukemia Research
Volume 29, Issue 8 , Pages 971-973, August 2005

Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML)

Outcome of discontinuation of imatinib therapy after achieving a molecular remission

Rıdvan Ali
- Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
- Corresponding author. Tel.: +90 224 4428400; fax: +90 224 4428060.
Fahir Özkalemkaş
- Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
Tülay Özçelik
- Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
Vildan Özkocaman
- Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
Ülkü Ozan
- Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey
Yalçın Kimya
- Department of Obstetrics and Gynecology, Uludag University School of Medicine, Bursa, Turkey
Nilgün Köksal
- Division of Neonatology, Department of Pediatrics, Uludag University School of Medicine, Bursa, Turkey
Tuna Gülten
- Department of Medical Genetics, Uludag University School of Medicine, Bursa, Turkey
Tahsin Yakut
- Department of Medical Genetics, Uludag University School of Medicine, Bursa, Turkey
Ahmet Tunalı
- Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey

Received 1 January 2005 published online 07 March 2011.

Abstract

Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation.

Keywords: Chronic myelogenous leukemia, Pregnancy, Imatinib